Venetoclax Combined With FLAG-IDA in Refractory or Relapsed Acute Myeloid Leukemia.

Introduction: The prognosis of patients with refractory or relapsed AML (R/R-AML) is very limited. To (re)achieve complete remission, there has recently been increasing evidence that the combination of venetoclax (VEN) with chemotherapy is associated with improved outcomes.

Patients And Methods: Our retrospective, single-center study of 53 R/R-AML patients with a median follow-up time of 11.